Kevin Whittlesey is Director of Program and Alliance Management at 4D Molecular Therapeutics, managing the development of a portfolio of AAV-based gene therapy products for a range of disease areas. He previously spent five years at the California Institute for Regenerative Medicine (CIRM) managing translational cell therapy projects in preclinical and clinical development. Prior to his time at CIRM, he was a Commissioner’s Fellow at the Food and Drug Administration based in the Office of the Commissioner working with both the Center for Biologics Evaluation and Research and the Center for Devices and Radiological Health on regenerative medicine product regulatory policy. Kevin also served as a science policy advisor in the U.S. House of Representatives first for Representative Doris Matsui and then for Representative Anna Eshoo. He was also awarded a Christine Mirzayan Science and Technology Policy Fellowship at the National Academy of Sciences. Kevin earned his Ph.D. in biological sciences from Northwestern University and conducted a postdoctoral fellowship at Aastrom Biosciences.